6,678 trials
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Safety With Respect to the Assessment of Conjunctival Hyperaemia in the Worse Eye — 4; 1; 5; 29 Participants — p=<0.0001
Japanese Encephalitis
Primary: Percentage of Participants With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 98.0; 99.3; 100.0; 100.0 percentage of participants
Allergic Conjunctivitis
Primary: Tear Osmolarity — 303; 303 mOsM/L
Osteoarthritis, Knee
Primary: Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to 24 Hours After First Dose of Study Drug Treatment. — 27.03; 20.0; 23.08; 20.0 percentage…
Carcinoma, Non-Small-Cell Lung · ErbB Receptors
Primary: Percentage of Participants Reporting an Adverse Event (AE) Leading to Dose Reduction of Afatinib — 32.0 Percentage
Pain · Fracture
Primary: Change in Score on Visual Analog Scale (VAS) — 3.28; 1.47; 3.62; 3.91 score on a scale
Primary Biliary Cirrhosis
Primary: Biochemical Response — 1 Participants
Peer Review, Research
Primary: Area Under the Curve (AUC 0-∞ ) ng∙h/mL — 60.1; 64.2 ng∙h/mL
Cystic Fibrosis
Primary: FEV1 as a Measure of Lung Function — .35 percentage of liters
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
Abortion Second Trimester
Primary: Maximum Pain Score — 4.66; 6.51 score on a scale
Diabetes Mellitus Type 2
Primary: Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment. — 0.30769; -0.00352 Percentage of GLSLV — p=0.504
Osteoarthritis, Knee
Primary: Levels of Plasmin Anti-plasmin (PAP) - Marker of Fibrinolysis — 117.8; 1280.7; 1032; 1041.2 ug/L
Migraine
Primary: Pain-relief — 5.6; 5.1; 2.25; 2.2 units on a scale*hr
Cognitive Dysfunction
Primary: Number of Cases Developing POCD — 10; 21 Participants